Dr. Charles Geyer, Jr.. presented findings from the NSABP B-59/GBG-96-GeparDouze phase III trial, evaluating the addition of atezolizumab to neoadjuvant chemotherapy, followed by adjuvant atezolizumab, in stage II-III triple-negative breast cancer (TNBC).- pCR rates improved from 57% to 63% with atezolizumab.
- 4-year event-free survival (EFS) was 85.2% vs. 81.9% in the control arm, but the difference was not statistically significant (HR = 0.8, p = 0.08).
- Overall survival (OS) remained similar between the two groups (90.2% vs. 89.5%).
- The safety profile of atezolizumab with chemotherapy was consistent with prior TNBC studies.
While the primary endpoint was not met, these findings underscore the importance of biomarker-driven research to better identify TNBC patients who may benefit from immune checkpoint inhibitors in both neoadjuvant and adjuvant settings.
A sincere thank you to Dr. Charles Geyer, Jr. for his contributions to advancing research in TNBC treatment.
